JP7489323B2 - Ｃｄ７３阻害剤 - Google Patents

Ｃｄ７３阻害剤 Download PDF

Info

Publication number
JP7489323B2
JP7489323B2 JP2020560361A JP2020560361A JP7489323B2 JP 7489323 B2 JP7489323 B2 JP 7489323B2 JP 2020560361 A JP2020560361 A JP 2020560361A JP 2020560361 A JP2020560361 A JP 2020560361A JP 7489323 B2 JP7489323 B2 JP 7489323B2
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560361A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019213174A5 (https=
JP2021522280A5 (https=
JP2021522280A (ja
Inventor
ドュ，シャオフイ
エクステロウィッツ，ジョン
ファンティン，ヴァレリア，アール．
サン，ダチン
イェ，チョウピン
ムーア，ジャレド
ザヴォロティンスカヤ，タチアナ
ブランク，ブライアン，アール．
リュウ，ヨサップ
ウー，ケジア
ズー，リュウシェン
ファム，ジョニー
カワイ，ヒロユキ
Original Assignee
オリック ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリック ファーマシューティカルズ，インク． filed Critical オリック ファーマシューティカルズ，インク．
Publication of JP2021522280A publication Critical patent/JP2021522280A/ja
Publication of JPWO2019213174A5 publication Critical patent/JPWO2019213174A5/ja
Publication of JP2021522280A5 publication Critical patent/JP2021522280A5/ja
Priority to JP2024078186A priority Critical patent/JP2024112864A/ja
Application granted granted Critical
Publication of JP7489323B2 publication Critical patent/JP7489323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2020560361A 2018-04-30 2019-04-30 Ｃｄ７３阻害剤 Active JP7489323B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024078186A JP2024112864A (ja) 2018-04-30 2024-05-13 Ｃｄ７３阻害剤

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862664841P 2018-04-30 2018-04-30
US62/664,841 2018-04-30
US201862737647P 2018-09-27 2018-09-27
US62/737,647 2018-09-27
US201862757714P 2018-11-08 2018-11-08
US62/757,714 2018-11-08
US201862777697P 2018-12-10 2018-12-10
US62/777,697 2018-12-10
US201962810790P 2019-02-26 2019-02-26
US62/810,790 2019-02-26
PCT/US2019/030068 WO2019213174A1 (en) 2018-04-30 2019-04-30 Cd73 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024078186A Division JP2024112864A (ja) 2018-04-30 2024-05-13 Ｃｄ７３阻害剤

Publications (4)

Publication Number Publication Date
JP2021522280A JP2021522280A (ja) 2021-08-30
JPWO2019213174A5 JPWO2019213174A5 (https=) 2022-04-26
JP2021522280A5 JP2021522280A5 (https=) 2022-04-26
JP7489323B2 true JP7489323B2 (ja) 2024-05-23

Family

ID=68386646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560361A Active JP7489323B2 (ja) 2018-04-30 2019-04-30 Ｃｄ７３阻害剤
JP2024078186A Pending JP2024112864A (ja) 2018-04-30 2024-05-13 Ｃｄ７３阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024078186A Pending JP2024112864A (ja) 2018-04-30 2024-05-13 Ｃｄ７３阻害剤

Country Status (13)

Country Link
US (4) US11325938B2 (https=)
EP (2) EP3787635B1 (https=)
JP (2) JP7489323B2 (https=)
KR (1) KR20210018255A (https=)
CN (2) CN112423764A (https=)
AU (1) AU2019261976B2 (https=)
BR (1) BR112020022068A2 (https=)
CA (1) CA3098493A1 (https=)
IL (1) IL304348B2 (https=)
MX (2) MX2020011542A (https=)
SG (1) SG11202010790XA (https=)
TW (1) TW202014182A (https=)
WO (1) WO2019213174A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024164093A (ja) * 2019-10-30 2024-11-26 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
EP3810109B1 (en) * 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
AU2019288495B2 (en) 2018-06-21 2024-02-08 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
EP4251633A4 (en) * 2020-11-25 2024-09-25 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF
WO2022237747A1 (zh) 2021-05-11 2022-11-17 四川海思科制药有限公司 小分子cd73拮抗剂及其用途
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2024076873A1 (en) * 2022-10-03 2024-04-11 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
CN116217644B (zh) * 2023-04-24 2023-08-08 南京颐媛生物医学研究院有限公司 抗冠状病毒核糖核苷类化合物及其制备方法和应用
WO2025162964A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of endometriosis
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
JP2017513955A (ja) 2014-04-25 2017-06-01 ビテ・ファーマシューティカルズ・インコーポレイテッドＶｉｔａｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
WO2018049145A1 (en) 2016-09-09 2018-03-15 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
WO2018067424A1 (en) 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
JP2020515559A (ja) 2017-03-31 2020-05-28 ぺロトン セラピューティクス，インク． Ｃｄ７３阻害剤とその使用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
WO2017098421A1 (en) * 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
HUE063388T2 (hu) * 2016-01-08 2024-01-28 Arcus Biosciences Inc Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása
EP3541396A4 (en) 2016-11-18 2020-07-22 Arcus Biosciences, Inc. CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS
JP7138351B2 (ja) 2016-12-22 2022-09-16 キャリセラ バイオサイエンシーズ， インコーポレイテッド エクトヌクレオチダーゼ阻害剤およびその使用方法
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
US11377469B2 (en) 2017-11-03 2022-07-05 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
EP3810109B1 (en) 2018-05-31 2024-08-07 Peloton Therapeutics, Inc. Compounds and compositions for inhibiting cd73
AU2019288495B2 (en) 2018-06-21 2024-02-08 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
EP3843714B1 (en) 2018-08-27 2025-11-12 Arcus Biosciences, Inc. Cd73 inhibitors
KR20220024629A (ko) 2019-06-20 2022-03-03 칼리테라 바이오사이언시즈, 인코포레이티드 엑토뉴클레오티다제 억제제 및 이의 사용 방법
US12544391B2 (en) 2019-07-16 2026-02-10 Oric Pharmaceuticals, Inc. CD73 inhibitors
HUE072504T2 (hu) 2019-10-30 2025-11-28 Oric Pharmaceuticals Inc CD73-inhibitorok

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
JP2017513955A (ja) 2014-04-25 2017-06-01 ビテ・ファーマシューティカルズ・インコーポレイテッドＶｉｔａｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
WO2018049145A1 (en) 2016-09-09 2018-03-15 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
WO2018067424A1 (en) 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
JP2020515559A (ja) 2017-03-31 2020-05-28 ぺロトン セラピューティクス，インク． Ｃｄ７３阻害剤とその使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024164093A (ja) * 2019-10-30 2024-11-26 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
JP7688769B2 (ja) 2019-10-30 2025-06-04 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤

Also Published As

Publication number Publication date
CA3098493A1 (en) 2019-11-07
US11325938B2 (en) 2022-05-10
WO2019213174A1 (en) 2019-11-07
MX2023002507A (es) 2023-03-13
BR112020022068A2 (pt) 2021-04-20
US20240124512A1 (en) 2024-04-18
MX2020011542A (es) 2020-11-24
CN112423764A (zh) 2021-02-26
JP2024112864A (ja) 2024-08-21
US20250368677A1 (en) 2025-12-04
IL304348B2 (en) 2024-08-01
EP4674481A3 (en) 2026-03-04
EP4674481A2 (en) 2026-01-07
SG11202010790XA (en) 2020-11-27
CN120699076A (zh) 2025-09-26
IL304348B1 (en) 2024-04-01
KR20210018255A (ko) 2021-02-17
US20220220147A1 (en) 2022-07-14
EP3787635A4 (en) 2022-03-02
EP3787635B1 (en) 2025-09-17
US20210047359A1 (en) 2021-02-18
AU2019261976B2 (en) 2025-01-23
US11807658B2 (en) 2023-11-07
AU2019261976A1 (en) 2020-12-03
TW202014182A (zh) 2020-04-16
JP2021522280A (ja) 2021-08-30
EP3787635A1 (en) 2021-03-10
IL304348A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
JP7489323B2 (ja) Ｃｄ７３阻害剤
JP7688769B2 (ja) Ｃｄ７３阻害剤
US11377469B2 (en) CD73 inhibitors
WO2018208980A1 (en) Cd73 inhibitors
HK40047148B (en) Cd73 inhibitors
HK40047148A (en) Cd73 inhibitors
EA043919B1 (ru) Ингибиторы cd73
HK40081385B (en) Cd73 inhibitors
HK40081385A (en) Cd73 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230309

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240513

R150 Certificate of patent or registration of utility model

Ref document number: 7489323

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150